News

Transgender women keep their prostates after gender-affirming surgery, and as a result are still at risk for prostate cancer. But the extent to which they’re at risk has been unclear up to now. A first-of-its-kind study led by UC San Francisco estimates the risk at about 14 cases per 10,000 people

UCSF Health hospitals at Mission Bay and Parnassus Heights earned an “A” Hospital Safety Grade from The Leapfrog Group for spring 2023 – a national recognition of excellence for protecting patients from preventable harm and errors. The safety group gave the highest rating to the UCSF Helen Diller

Beginning May 9, UC San Francisco will be the first hospital in California, and one of only a few nationwide, to offer pharmacogenetic testing. The test will provide critical clues about a patient’s unique genetic makeup, enabling pharmacists to tailor medications and dosages accordingly. The

UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable. UCSF’s Division of Surgical Oncology is currently

Eleven investigators and teams were awarded grants in support of cancer research projects in the fall 2022 cycle of the UCSF Resource Allocation Program (RAP). Funded by various agencies across UCSF, the awards span a range of topics from targeting cell growth in pancreatic cancer to predicting head

Today, patients with prostate cancer can be effectively treated with surgery, radiation, or androgen deprivation therapy. However, a significant fraction of patients progress to metastatic, castration-resistant prostate cancer (mCRPC), which is resistant to these treatments. Dr. Anil Bidkar, Dr